We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$13.3B
AUM Growth
+$1.51B
Cap. Flow
+$1.01B
Cap. Flow %
7.58%
Top 10 Hldgs %
83.56%
Holding
124
New
10
Increased
16
Reduced
22
Closed
5

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$1.09B
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$84.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$44.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$144M
2
ABLX
Ablynx NV
ABLX
+$119M
3
NKTR icon
Nektar Therapeutics
NKTR
+$29.3M
4
EXEL icon
Exelixis
EXEL
+$13.4M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.23%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFI
101
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.11M 0.01%
580,400
– –
TTOO
102
DELISTED
T2 Biosystems, Inc
TTOO
$774K 0.01%
20
– –
JNCE
103
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$766K 0.01%
100,000
– –
TARA icon
104
Protara Therapeutics
TARA
$228M
$732K 0.01%
7,465
– –
AIXC
105
AIxCrypto Holdings Inc
AIXC
$22.7M
$720K 0.01%
22
– –
STML
106
DELISTED
Stemline Therapeutics, Inc.
STML
$715K 0.01%
44,524
-243,303
-85% -$4.34M
AFMD
107
DELISTED
Affimed
AFMD
$660K 0.01%
40,000
– –
BDSI
108
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$620K ﹤0.01%
210,021
– –
FLGT icon
109
Fulgent Genetics
FLGT
$548M
$518K ﹤0.01%
125,000
– –
MTEM
110
DELISTED
Molecular Templates, Inc.
MTEM
$379K ﹤0.01%
4,827
– –
AKTX
111
Akari Therapeutics
AKTX
$15.3M
$115K ﹤0.01%
73
-352
-83% -$553K
BGMSP
112
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$89K ﹤0.01%
13,253
– –
BTX.WS
113
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$1K ﹤0.01%
20,084
– –
NKTR icon
114
Nektar Therapeutics
NKTR
$2.53B
– –
-18,360
Closed -$29.3M
NVAX icon
115
Novavax
NVAX
$1.47B
– –
-100,000
Closed -$4.2M
ABLX
116
DELISTED
Ablynx NV
ABLX
– –
-2,176,802
Closed -$119M
AVXS
117
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-1,167,157
Closed -$144M
IMDZ
118
DELISTED
Immune Design Corp.
IMDZ
– –
-148,937
Closed -$491K
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2018 Portfolio in Review

As of Q2 2018, Julian Baker held 124 positions worth $13.3B, up 13% from $11.8B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker deployed $1.01B of net new capital in Q2 2018, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Exelixis, an estimated $13.4M trimmed.

  • Julian Baker's largest Q2 2018 buy was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.
  • Julian Baker added most to BeOne Medicines Ltd in Q2 2018, an estimated $1.09B increase.
  • Julian Baker's biggest Q2 2018 reduction was Exelixis, cutting an estimated $13.4M.
  • Julian Baker fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $144M.
  • Julian Baker's ten largest holdings make up 84% of its $13.3B portfolio in Q2 2018.
  • Julian Baker opened 10 new positions and closed 5 in Q2 2018.
  • Julian Baker's portfolio value rose 13% quarter-over-quarter to $13.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.